Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Fyn Specifically Regulates the Activity of Red Cell Glucose-6-Phosphate-Dehydrogenase

Blood (2019) 134 (Supplement_1): 3527.

https://doi.org/10.1182/blood-2019-125709

Published: 2019

Journal Articles

Long-Term Follow-up after Treatment Discontinuation in Patients with Chronic Myeloid Leukemia: The Korean Imatinib Discontinuation (KID) Study

Dae Young Zang, MD PhD, Won Sik Lee, MD PhD, Yeung-Chul Mun, Young Rok Do, PhD MD, Sukjoong Oh, MD PhD, Sung-Eun Lee, MD PhD, Soo Young Choi, Dong-Wook Kim, MD PhD

Blood (2018) 132 (Supplement 1): 4252.

https://doi.org/10.1182/blood-2018-99-118026

Published: 2018

Journal Articles

Prognostic Implication of Early Molecular Response at 3 Months in Chronic Myeloid Leukemia Patients: A Comparison of Imatinib and Second Generation Tyrosine Kinase Inhibitors

Dong-Wook Kim, MD PhD, Sung-Eun Lee, MD PhD, Soo Young Choi, Dae Young Zang, MD PhD, Won-Sik Lee, Yeung-Chul Mun, Young Rok Do, PhD MD, Sukjoong Oh, MD PhD

Blood (2018) 132 (Supplement 1): 3017.

https://doi.org/10.1182/blood-2018-99-117631

Published: 2018

Journal Articles

Association of Gene Expression Patterns in Bone Marrow Cells with Likelihood of Treatment Free Remission after TKI Discontinuation

Jianbo He, MD, Sahee Park, Soo Young Choi, David Crossman, Bin Zhang, PhD, Puneet Agarwal, PhD, Andrew Zhang, Su Chu, MD, Dong-Wook Kim, MD PhD, Ravi Bhatia, MD

Blood (2018) 132 (Supplement 1): 1721.

https://doi.org/10.1182/blood-2018-99-114137

Published: 2018

Journal Articles

Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease

Blood (2018) 132 (9): 948–961.

https://doi.org/10.1182/blood-2018-02-832253

Published: 2018

Includes: Supplemental data

Journal Articles

Integrative Genomics Reveals Cancer Associated Mutations Are Common at Diagnosis of CML in Patients with Poor Response to TKI Therapy

Blood (2017) 130 (Supplement 1): 251.

https://doi.org/10.1182/blood.V130.Suppl_1.251.251

Published: 2017

Journal Articles

Mir-424 and Mir-503 Regulates Cobll1 Expression during the CML Progression

Seung Hun Han, PhD, Soo-Hyun Kim, Kim Hyoung-June, PhD, Lee Yoonsung, PhD, Soo-Young Choi, Park Gyeongsin, Kim Do-Hyun, Lee Aram, Kim Jongmin, PhD, Choi Je-Min, PhD, Kim Yonghwan, PhD, Myung Kyungjae, PhD, Kim Hongtae, PhD, Dong-Wook Kim, MD PhD

Blood (2017) 130 (Supplement 1): 4177.

https://doi.org/10.1182/blood.V130.Suppl_1.4177.4177

Published: 2017

Journal Articles

Prevalence and Risk Predictive Factors of Comorbid Malignancies in Patients with Chronic Myeloid Leukemia

Tong-Yoon Kim, MD, Sung-Eun Lee, Soo-Hyun Kim, Soo-Young Choi, Eun-Jung Jang, Dong-Wook Kim, MD PhD

Blood (2016) 128 (22): 1900.

https://doi.org/10.1182/blood.V128.22.1900.1900

Published: 2016

Journal Articles

Predictive Value of 3-Month Early Molecular Response in New Chronic Phase Chronic Myeloid Leukemia Patients Treated with Radotinib

Blood (2015) 126 (23): 4053.

https://doi.org/10.1182/blood.V126.23.4053.4053

Published: 2015

Journal Articles

Peroxiredoxin-2: A Novel Factor Involved in Iron Homeostasis

Alessandro Mattè, PhD, Luigia De Falco, Enrica Federti, Sonia Levi, PhD, Achille Iolascon, MD PhD, Giorgia Federico, Narla Mohandas, DSc, Anne Janin, MD PhD, Mariasole Bruno, Christophe Leboeuf, PhD, Soo Young Choi, PhD, Dae Won Kim, Francesco Dima, MD, Angela Siciliano, Lucia De Franceschi, MD

Blood (2015) 126 (23): 406.

https://doi.org/10.1182/blood.V126.23.406.406

Published: 2015

Journal Articles

Outcome of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients Treated with Various Frontline Second-Generation Tyrosine Kinase Inhibitors: A Single-Center Experience

Sung-Eun Lee, Soo Young Choi, Soo-Hyun Kim, Hye-Young Song, Hea-Lyun Yoo, Mi-Young Lee, Ki-Hoon Kang, Hee-Jeong Hwang, Eun-Jung Jang, Dong-Wook Kim

Blood (2015) 126 (23): 1595.

https://doi.org/10.1182/blood.V126.23.1595.1595

Published: 2015

Journal Articles

Results from the Korean Imatinib Discontinuation Study (KIDS): Updated Data with 15-Month Median Follow up

Blood (2014) 124 (21): 3155.

https://doi.org/10.1182/blood.V124.21.3155.3155

Published: 2014

Journal Articles

Long-Term Assessment of Dasatinib-Induced Pulmonary Arterial Hypertension in Chronic Myeloid Leukemia

Jee Hyun Kong, Dr, Young-Woo Jeon, Sung-Eun Lee, Soo Young Choi, Soo-Hyun Kim, Yun Jeong Oh, Jin-Eok Park, Hye-Rim Jeon, Eun-Jung Jang, Suk Joong Oh, Dong-Wook Kim, MD PhD

Blood (2014) 124 (21): 5535.

https://doi.org/10.1182/blood.V124.21.5535.5535

Published: 2014

Journal Articles

Distinct Associations Between UGT1A1 Gene Promoter Polymorphism and Hyperbilirubinemia in Korean CML Patients Treated with Nilotinib and Radotinib

Soo-Hyun Kim, Soo Young Choi, Sung-Eun Lee, Yun Jeong Oh, Hae Lyun Yoo, Eun-Jung Jang, Mi-yeon Choi, Moon-mi Jang, Hyeoung Joon Kim, MD, Jae-Yong Kwak, MD PhD, Hawk Kim, MD, PhD., Young-Rok Do, PhD, Dong-Wook Kim, MD PhD

Blood (2014) 124 (21): 5511.

https://doi.org/10.1182/blood.V124.21.5511.5511

Published: 2014

Journal Articles

Efficacy of Nilotinib Vs High-Dose Imatinib Vs Sustaining Standard-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Response to Frontline Imatinib

Soo Young Choi, Sung-Eun Lee, Yun jeong Oh, Soo-Hyun Kim, Richard C. Woodman, Tomasz Szczudlo, MD, Saengsuree Jootar, MD, Hyeoung-Joon Kim, MD PhD, Sang Kyun Sohn, MD PhD, Joon Seong Park, MD, Sung-Hyun Kim, MD PhD, Dae-Young Zang, Suk-Joong Oh, Dong-Wook Kim, MD PhD

Blood (2014) 124 (21): 1816.

https://doi.org/10.1182/blood.V124.21.1816.1816

Published: 2014

Journal Articles

BCR-ABL1 Transcript of 7.93% at 3 Months Is an Early Predictor for Long-Term Survival to Second-Line Therapy Using Next Generation Tyrosine Kinase Inhibitors in Imatinib-Resistant Chronic Phase Chronic Myeloid Leukemia

Sung-Eun Lee, Soo Young Choi, Yun Jeong Oh, Soo-Hyun Kim, Hye-Young Song, Hea-Lyun Yoo, Mi-Young Lee, Moon-Jung Chae, Ki-Hoon Kang, Hee-Jeong Hwang, Eun-Jung Jang, Dong-Wook Kim, MD PhD

Blood (2014) 124 (21): 4564.

https://doi.org/10.1182/blood.V124.21.4564.4564

Published: 2014

Journal Articles

Six-Year Follow-Up Of Dasatinib-Related Pulmonary Arterial Hypertension (PAH) For Chronic Myeloid Leukemia In Single Center

Young-Woo Jeon, M.D., Sung-Eun Lee, M.D., Soo-Hyun Kim, Soo-Young Choi, Jin-Eok Park, Hye-Rim Jeon, Eun-Jung Jang, Dong-Wook Kim, MD, PhD

Blood (2013) 122 (21): 4017.

https://doi.org/10.1182/blood.V122.21.4017.4017

Published: 2013

Journal Articles

Safety and Efficacy Of Imatinib In Elderly Patients With Chronic-Phase Chronic Myeloid Leukemia: Analysis Of Outcome For < 60 Years Versus ≥ 60 Years

Young-Woong Won, M.D., Ph.D., DongWook Kim, Sung-Eun Lee, M.D., Soo Young Choi, Soo-Hyun Kim, Eun-Jung Jang

Blood (2013) 122 (21): 4039.

https://doi.org/10.1182/blood.V122.21.4039.4039

Published: 2013

Journal Articles

Plasma Imatinib Trough Level Is a Predictor For 3-Month Early Molecular Response In New CP CML Patients

Sung-Eun Lee, M.D., Soo Young Choi, Soo-Hyun Kim, Yun Jeong Oh, Jin-Eok Park, Eun-Jung Jang, Dong-Wook Kim, MD, PhD

Blood (2013) 122 (21): 2716.

https://doi.org/10.1182/blood.V122.21.2716.2716

Published: 2013

NARROW

Fyn Specifically Regulates the Activity of Red Cell Glucose-6-Phosphate-Dehydrogenase

Long-Term Follow-up after Treatment Discontinuation in Patients with Chronic Myeloid Leukemia: The Korean Imatinib Discontinuation (KID) Study

Prognostic Implication of Early Molecular Response at 3 Months in Chronic Myeloid Leukemia Patients: A Comparison of Imatinib and Second Generation Tyrosine Kinase Inhibitors

Association of Gene Expression Patterns in Bone Marrow Cells with Likelihood of Treatment Free Remission after TKI Discontinuation

Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease

Integrative Genomics Reveals Cancer Associated Mutations Are Common at Diagnosis of CML in Patients with Poor Response to TKI Therapy

Mir-424 and Mir-503 Regulates Cobll1 Expression during the CML Progression

Comparison of Molecular Kinetics after the First and Second Imatinib Discontinuation: Results from the KID Study

Prevalence and Risk Predictive Factors of Comorbid Malignancies in Patients with Chronic Myeloid Leukemia

Predictive Value of 3-Month Early Molecular Response in New Chronic Phase Chronic Myeloid Leukemia Patients Treated with Radotinib

Peroxiredoxin-2: A Novel Factor Involved in Iron Homeostasis

Outcome of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients Treated with Various Frontline Second-Generation Tyrosine Kinase Inhibitors: A Single-Center Experience

Results from the Korean Imatinib Discontinuation Study (KIDS): Updated Data with 15-Month Median Follow up

Long-Term Assessment of Dasatinib-Induced Pulmonary Arterial Hypertension in Chronic Myeloid Leukemia

Distinct Associations Between UGT1A1 Gene Promoter Polymorphism and Hyperbilirubinemia in Korean CML Patients Treated with Nilotinib and Radotinib

Efficacy of Nilotinib Vs High-Dose Imatinib Vs Sustaining Standard-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Response to Frontline Imatinib

BCR-ABL1 Transcript of 7.93% at 3 Months Is an Early Predictor for Long-Term Survival to Second-Line Therapy Using Next Generation Tyrosine Kinase Inhibitors in Imatinib-Resistant Chronic Phase Chronic Myeloid Leukemia

Six-Year Follow-Up Of Dasatinib-Related Pulmonary Arterial Hypertension (PAH) For Chronic Myeloid Leukemia In Single Center

Safety and Efficacy Of Imatinib In Elderly Patients With Chronic-Phase Chronic Myeloid Leukemia: Analysis Of Outcome For < 60 Years Versus ≥ 60 Years

Plasma Imatinib Trough Level Is a Predictor For 3-Month Early Molecular Response In New CP CML Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only